Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma (SYSTHER)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Blood Transfusion Centre of Slovenia.
Recruitment status was  Recruiting
Information provided by:
Blood Transfusion Centre of Slovenia Identifier:
First received: November 27, 2009
Last updated: January 12, 2010
Last verified: November 2009
Interventional study of modulation of immune response in patients with pancreatic tubular adenocarcinoma after resection and gemcitabine treatment. When included, patients are pre-treated with moderate doses of cyclophosphamide. Then infusions of allogeneic mononuclear cells are given.

Condition Intervention Phase
Pancreatic Tubular Adenocarcinoma
Biological: MIS
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Further study details as provided by Blood Transfusion Centre of Slovenia:

Primary Outcome Measures:
  • PROGRESSION FREE SURVIVAL [ Time Frame: 1 YEAR ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: April 2009
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cell infusion Biological: MIS
Cell infusion


Ages Eligible for Study:   30 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ECOG performance status 0-2 at the time of inclusion
  • Following R0 or R1 pancreatic tubular adenocarcinoma resection and adjuvant gemcitabine treatment

Exclusion Criteria:

  • Pregnancy
  • Less than 3 mths expected survival
  • Serious comorbidity
  • Age above 70 yrs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01021800

Contact: Borut Stabuc, MD PhD +38615222210
Contact: Lojze Smid, MD

University Medical Centre Ljubljana, Department for Gastroenterolgy Recruiting
Ljubljana, Slovenia, 1000
Contact: Borut Stabuc, MD, PhD    +38615222210   
Contact: Lojze Smid, MD   
Principal Investigator: Borut Stabuc, MD, PhD         
Sponsors and Collaborators
Blood Transfusion Centre of Slovenia
  More Information

Responsible Party: Primoz Rozman, MD PhD, Blood Transfusion Centre of Slovenia Identifier: NCT01021800     History of Changes
Other Study ID Numbers: MIS 
Study First Received: November 27, 2009
Last Updated: January 12, 2010
Health Authority: Slovenia: Agency for Medicinal Products and Medical Devices of the Republic of Slovenia

Keywords provided by Blood Transfusion Centre of Slovenia:
Pancreatic tubular adenocarcinoma adjuvant setting

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial processed this record on May 26, 2016